Business Wire

Experian Acquires Behavioral Analytics Pioneer NeuroID

13.8.2024 17:45:00 EEST | Business Wire | Press release

Share

Experian® — the global data and technology company — announced today that it has acquired NeuroID, an industry leader in behavioral analytics. NeuroID’s modern and frictionless capabilities amplify Experian’s fraud risk suite by providing a new layer of insight into digital behavioral signals and analytics observed for both new and returning users throughout the customer lifecycle, including account openings, logins and transactions.

NeuroID’s behavioral analytics solutions are available now through CrossCore® on the Experian Ascend Technology Platform™ as a key fraud-detection capability. Experian’s identity verification and fraud prevention solutions helped clients avoid an estimated $15 billion in fraud losses globally last year. With NeuroID seamlessly integrated into Experian, clients can use one service provider to proactively monitor and analyze a user’s real-time digital behavior (for example, how they navigate a form and enter information).

The emergence of generative AI-driven fraud has motivated companies across industries from financial services to healthcare and e-commerce to seek new types of fraud-detection technology, such as behavioral analytics, within their originations and account management fraud strategies. Insights from behavioral analytics help mitigate fraud in real time and prevent identity theft, account takeover, bot attacks, next-generation bot attacks and fraud rings — empowering businesses to provide a seamless customer experience.

“Our acquisition of NeuroID highlights our commitment to provide our clients with world-class data, analytics and insights to prevent fraud. Together with NeuroID, we’re excited to build new blended offerings that detect risk but also empower businesses to confidently navigate the online landscape and trust in their transactions,” said Robert Boxberger, President of Experian’s North American Identity & Fraud business. “In today’s highly competitive and digital-first world, the use of behavioral analytics is now vital for innovating for the future of fighting fraud.”

“We are in a new era of fraud driven by AI. Companies are under immense pressure to rapidly innovate and advance their approach to fighting fraud. NeuroID unlocks a new view into a user’s riskiness based on behavioral interactions,” said Jack Alton, CEO at NeuroID. “This view arms companies with a proactive, first line of defense to detect sophisticated fraud rings and bot attacks. By joining forces with Experian, we’re looking forward to helping companies confidently navigate this new era with solutions that enable more secure and frictionless experiences.”

To learn more, please visit https://www.experian.com/business/solutions/fraud-management.

About NeuroID

NeuroID, a global leader in behavioral analytics, provides a privacy-centered first line of fraud defense for digital businesses. NeuroID’s software determines whether a user is a human or a bot, and if the human presents risk, based on how familiar they are with the data they enter and interact with. NeuroID’s proprietary technology enables deep visibility into digital interactions (without collecting personal data) to proactively monitor, alert, and act against fraud. Paired with expert guidance, NeuroID accelerates modern risk management so global leaders can see fraud faster, reduce losses and increase savings. More information about NeuroID’s products and services can be found at https://www.neuro-id.com/.

About Experian

Experian is a global data and technology company, powering opportunities for people and businesses around the world. We help to redefine lending practices, uncover and prevent fraud, simplify healthcare, deliver digital marketing solutions, and gain deeper insights into the automotive market, all using our unique combination of data, analytics and software. We also assist millions of people to realise their financial goals and help them to save time and money. We operate across a range of markets, from financial services to healthcare, automotive, agrifinance, insurance, and many more industry segments.

We invest in talented people and new advanced technologies to unlock the power of data and innovate. As a FTSE 100 Index company listed on the London Stock Exchange (EXPN), we have a team of 22,500 people across 32 countries. Our corporate headquarters are in Dublin, Ireland. Learn more at experianplc.com.

Experian and the Experian trademarks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240813630475/en/

Contacts

Media queries
Annie Russell
1 949 683 5243
annie.russell@experian.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces FDA Approval of Jakafi XR™ (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease2.5.2026 00:28:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets for the treatment of adults with intermediate- or high-risk myelofibrosis (MF); adults with polycythemia vera (PV) who have had an inadequate response to or are intolerant of hydroxyurea; as well as adults and children aged 12 years and older with steroid-refractory acute graft-versus-host disease (GVHD) or chronic GVHD after failure of one or two lines of systemic therapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260501334677/en/ “The approval of Jakafi XR reinforces Incyte’s leadership in hematology and our focus on meeting the evolving needs of patients with myeloproliferative neoplasms (MPNs) and GVHD,” said Bill Meury, Chief Executive Officer, Incyte. “Jakafi XR offers appropriate patients and physicians a once-daily option, expanding choice without changing the well-

Barilla Hosts Surprise Formula 1® Family Reunion Dinner During Miami Race Weekend1.5.2026 19:08:00 EEST | Press release

A special invitation, a table, and a plate of pasta shared by people who are often apart. That’s all it took for Barilla to bring the spirit of togetherness to Miami during the opening day of the FORMULA 1® CRYPTO.COM MIAMI GRAND PRIX 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430832316/en/ Barilla hosts Arvid Lindblad, Mikaela Shiffrin, and Nico Rosberg with Chef Massimo Bottura at Torno Subito, where the Formula 1® community came together for a surprise dinner. Barilla, the Official Pasta Partner of Formula 1®, welcomed team members and their families to Torno Subito Miami, the restaurant by three-Michelin-starred Chef Massimo Bottura, with the kitchen led by Chef Bernardo Paladini, for an evening where engines were switched off and everyday life took center stage. The night also celebrated the start of the new partnership between Barilla and the Visa Cash App Racing Bulls (VCARB) Formula 1® Team, a meeting of

TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release

Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the

Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release

Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan

Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release

Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye